GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Cyclically Adjusted Book per Share

Diamyd Medical AB (FRA:DMN) Cyclically Adjusted Book per Share : €0.26 (As of Feb. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Diamyd Medical AB's adjusted book value per share for the three months ended in Feb. 2025 was €0.095. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.26 for the trailing ten years ended in Feb. 2025.

During the past 12 months, Diamyd Medical AB's average Cyclically Adjusted Book Growth Rate was -4.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -13.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Diamyd Medical AB was -13.30% per year. The lowest was -20.60% per year. And the median was -16.95% per year.

As of today (2025-05-28), Diamyd Medical AB's current stock price is €0.801. Diamyd Medical AB's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2025 was €0.26. Diamyd Medical AB's Cyclically Adjusted PB Ratio of today is 3.08.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Diamyd Medical AB was 16.65. The lowest was 1.63. And the median was 6.87.


Diamyd Medical AB Cyclically Adjusted Book per Share Historical Data

The historical data trend for Diamyd Medical AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Cyclically Adjusted Book per Share Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.27 0.19 0.16 0.15

Diamyd Medical AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.16 0.15 0.16 0.26

Competitive Comparison of Diamyd Medical AB's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Diamyd Medical AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Cyclically Adjusted PB Ratio falls into.


;
;

Diamyd Medical AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Diamyd Medical AB's adjusted Book Value per Share data for the three months ended in Feb. 2025 was:

Adj_Book= Book Value per Share /CPI of Feb. 2025 (Change)*Current CPI (Feb. 2025)
=0.095/133.7436*133.7436
=0.095

Current CPI (Feb. 2025) = 133.7436.

Diamyd Medical AB Quarterly Data

Book Value per Share CPI Adj_Book
201505 0.209 100.285 0.279
201508 0.144 99.829 0.193
201511 0.131 100.129 0.175
201602 0.110 100.253 0.147
201605 0.124 100.914 0.164
201608 0.089 100.968 0.118
201611 0.086 101.517 0.113
201702 0.066 102.037 0.087
201705 0.028 102.679 0.036
201708 0.157 103.138 0.204
201711 0.137 103.413 0.177
201802 0.116 103.678 0.150
201805 0.090 104.632 0.115
201808 0.071 105.197 0.090
201811 0.058 105.443 0.074
201902 0.108 105.641 0.137
201905 0.095 106.895 0.119
201908 0.082 106.716 0.103
201911 0.074 107.345 0.092
202002 0.124 106.742 0.155
202005 0.114 106.882 0.143
202008 0.099 107.571 0.123
202011 0.251 107.549 0.312
202102 0.276 108.190 0.341
202105 0.290 108.838 0.356
202108 0.252 109.780 0.307
202111 0.000 111.069 0.000
202202 0.342 112.834 0.405
202205 0.322 116.746 0.369
202208 0.258 120.573 0.286
202211 0.210 123.803 0.227
202302 0.177 126.321 0.187
202305 0.155 128.034 0.162
202308 0.166 129.560 0.171
202311 0.191 130.958 0.195
202402 0.169 132.046 0.171
202405 0.169 132.818 0.170
202408 0.127 132.052 0.129
202411 0.129 133.000 0.130
202502 0.095 133.744 0.095

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Diamyd Medical AB  (FRA:DMN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Diamyd Medical AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.801/0.26
=3.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Diamyd Medical AB was 16.65. The lowest was 1.63. And the median was 6.87.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Diamyd Medical AB Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Industry
Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines